Immunotherapy News and Research

Latest Immunotherapy News and Research

Lung cancer stem cells can be isolated and grown in preclinical models

A University of Cincinnati (UC) Cancer Institute lung cancer research team reports that lung cancer stem cells can be isolated-and then grown-in a preclinical model, offering a new avenue for investigating immunotherapy treatment options that specifically target stem cells.

14 Nov 2012

Internet may foresee height of allergy suffering

While it's believed that Nostradamus' prophecies predicted many historical events, his digital successor, the Internet, may be foreseeing the height of allergy suffering. According to allergist Leonard Bielory, M.D., American College of Allergy, Asthma and Immunology (ACAAI) board member, Google search volume is shedding light on the most common allergy symptoms, when searches peak and how they pertain to pollen types.

9 Nov 2012

Lone star tick causes alpha-gal meat sensitivity in regional population

Meat lovers living in the central and southern regions of the country might be opting for a vegetarian lifestyle if meat comes with an unwanted side of a life-threatening allergic reaction. According to a study presented at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), the lone star tick inhabiting these regions is the primary reason for what's known as a meat induced alpha-gal allergic reaction.

9 Nov 2012

Immunomic Therapeutics initiates JRC-LAMP-vax vaccine Phase I trial in Sugi allergy

Immunomic Therapeutics, Inc., a leader in developing novel allergy immunotherapies, announced today that it has dosed the first patient in a Phase I clinical trial of its lead candidate, JRC-LAMP-vax vaccine, at its clinical site in Honolulu, Hawaii. Initial subjects include Japanese ex-patriates previously exposed to Japanese red cedar, or "Sugi," as it is known in Japan.

9 Nov 2012

More than half of allergic children can tolerate baked hen's eggs

Avoiding sweet treats like pumpkin bread and cookies this holiday season might not be necessary for children with egg allergies. New studies presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting found 56 percent of allergic children can tolerate baked hen's egg, while 55 percent outgrow their egg allergy entirely.

9 Nov 2012

High family income, hygiene habits can increase risk of peanut allergies in children

Peanut allergies are rising among American children and one reason might be due to economic status. According to a new study presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, greater rates of peanut allergy are found in families with higher economic status. This supports the "hygiene hypothesis" of many allergists.

9 Nov 2012

Pevion launches Defensomes platform for broad spectrum immune enhancement

Pevion Biotech AG today announced the launch of a new program called Defensomes, a platform for broad spectrum immune enhancement via mechanisms of innate immunity. The proprietary technology is derived from a vaccine platform with a solid safety track record comprising more than 80 million doses applied to humans to date. Defensomes offer opportunities for a wide range of prophylactic and therapeutic indications, where boosting of the body's own natural defense is beneficial.

8 Nov 2012

Women more likely to develop spice allergy

Imagine a world where you could never dine away from home, wear makeup, smell of sweet perfumes or eat a large percentage of food on store shelves. According to allergists at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting that is kicking off today in Anaheim, Calif., that is the world for 2 to 3 percent of individuals living with a spice allergy.

8 Nov 2012

Celldex to present results from CDX-301 Phase 1 study in healthy volunteers

Celldex Therapeutics, Inc. today announced an upcoming data presentation at the American Society of Hematology 54th Annual Meeting and Exposition to be held in Atlanta, GA from December 8 through December 11, 2012.

6 Nov 2012

Bristol-Myers Squibb welcomes decision by NICE to recommend Yervoy for advanced melanoma

Today, Bristol-Myers Squibb is pleased to welcome the decision by The National Institute for Health and Clinical Excellence (NICE) to recommend Yervoy (ipilimumab) for the treatment of previously-treated advanced (unresectable or metastatic) melanoma within the Final Appraisal Determination (FAD).

3 Nov 2012

Weill Cornell researchers awarded Grand Challenges Explorations grants

Weill Cornell Medical College announced today that it is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation.

3 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Advaxis updates preliminary data from ADXS-HPV Phase 2 trial on cervical cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, updated preliminary data from an ongoing randomized 110 patient Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy.

1 Nov 2012

Radiation therapy protocol deviations associated with increased risk of treatment failure and overall mortality

Radiation therapy protocol deviations in clinical trials are associated with increased risk of treatment failure and overall mortality, according to a study entitled, “Radiotherapy Protocol Deviations are Associated with Inferior Clinical Outcomes: A Meta-analysis of Cooperative Group Clinical Trials” to be presented today at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston, MA.

30 Oct 2012

Positive results from Celldex’s CDX-1401 Phase 1 study on solid tumors

Celldex Therapeutics, Inc. today announced positive results demonstrating promising clinical effects in a Phase 1 study of CDX-1401 in solid tumors in combination with the toll-like receptor (TLR) agonists resiquimod and/or Poly ICLC.

30 Oct 2012

Autoantibody aids identification of hyperexcitability disorders

Researchers have found that testing for a glycine receptor autoantibody aids the identification of a broad spectrum of autoimmune brainstem/spinal cord hyperexcitability disorders.

29 Oct 2012

Nonclinical data on Provectus PV-10 oncology drug presented at 27th SITC

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented nonclinical data on PV-10 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting on October 26 and 27, 2012 in North Bethesda, MD.

29 Oct 2012

New treatments show promise for people with food allergies

New treatments are offering the prospect of eating without fear for the 15 million people in the United States with food allergies, according to the cover story in the current issue of Chemical & Engineering News.

26 Oct 2012

New findings on how OX40 activation affects T helper cells that target melanoma

Cancers arise in the body all the time. Most are nipped in the bud by the immune response, not least by its T cells, which detect telltale molecular markers-or antigens-on cancer cells and destroy them before they grow into tumors. Cancer cells, for their part, evolve constantly to evade such assassination. Those that succeed become full-blown malignancies. Yet, given the right sort of help, the immune system can destroy even these entrenched tumors.

25 Oct 2012

12-chemokine gene signature can predict presence of lymph node-like structures in MM

Researchers at Moffitt Cancer Center have discovered a unique immune gene signature that can predict the presence of microscopic lymph node-like structures in metastatic melanoma. The presence of these immune structures, the researchers said, appears to be associated with better survival and may indicate the possibility of selecting patients for immunotherapy based solely on the immune-related makeup of their tumors as an approach to personalized medicine.

25 Oct 2012

Immunotherapy News and Research

Latest Immunotherapy News and Research

Lung cancer stem cells can be isolated and grown in preclinical models

Internet may foresee height of allergy suffering

Lone star tick causes alpha-gal meat sensitivity in regional population

Immunomic Therapeutics initiates JRC-LAMP-vax vaccine Phase I trial in Sugi allergy

More than half of allergic children can tolerate baked hen's eggs

High family income, hygiene habits can increase risk of peanut allergies in children

Pevion launches Defensomes platform for broad spectrum immune enhancement

Women more likely to develop spice allergy

Celldex to present results from CDX-301 Phase 1 study in healthy volunteers

Bristol-Myers Squibb welcomes decision by NICE to recommend Yervoy for advanced melanoma

Weill Cornell researchers awarded Grand Challenges Explorations grants

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Advaxis updates preliminary data from ADXS-HPV Phase 2 trial on cervical cancer

Radiation therapy protocol deviations associated with increased risk of treatment failure and overall mortality

Positive results from Celldex’s CDX-1401 Phase 1 study on solid tumors

Autoantibody aids identification of hyperexcitability disorders

Nonclinical data on Provectus PV-10 oncology drug presented at 27th SITC

New treatments show promise for people with food allergies

New findings on how OX40 activation affects T helper cells that target melanoma

12-chemokine gene signature can predict presence of lymph node-like structures in MM

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Immunotherapy News and Research

Latest Immunotherapy News and Research

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in